New Data on Investigational Tralokinumab for Treatment of AD

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, a dermatologist and president of Oregon Medical Research Center in Portland, Oregon, discusses the newest phase 3 clinical data on tralokinumab (LEO Pharma).

Tralokinumab is an investigational monoclonal antibody that specifically neutralizes interleukin (IL)-13, a key driver of atopic dermatitis (AD) and is currently being evaluated by the FDA. Hear what he has to say about the newest data from the ECZTEND (NCT03587805) trial in the video below.